Uptake and Pricing of Biosimilars & the "Rebate Wall": A Value & Innovation Forum Multi-Perspective Briefing

Biosimilars continue to be a controversial subject long after Congress created a pathway for their approval. The Value & Innovation Forum prides itself on creating forums that present all sides of an issue as well as new and interesting angles beyond the hotly debated. This session provides an interesting discussion about the “rebate wall” controversy in biosimilars, a patient perspective, and where the FDA is headed next.

Speakers

  • John M. Clymer, Executive Director, National Forum for Heart Disease & Stroke Prevention
  • Nicole Braccio, PharmD, Policy Director, National Patient Advocate Foundation
  • Christine Simmon, JD, Senior Vice President, Policy & Strategic Alliances, Executive Director, Biosimilars Council, Association for Accessible Medicines
  • Sarah Yim, MD, Director, Office of Therapeutic Biologics and Biosimilars, Office of New Drugs, Center for Drug Evaluation & Research, U.S. Food and Drug Administration
  • Chad Pettit, Executive Director, Global Value Access and Policy, Amgen
  • Madelaine Feldman, MD, Practicing Rheumatologist, Founding Member & Past President, Rheumatology Alliance of Louisiana
Agenda

AGENDA

WELCOME

John M. ClymerJohn M. Clymer, Executive Director, National Forum for Heart Disease & Stroke Prevention
Bio

 


MODERATOR

Nicole Braccio, PharmD, Policy Director, National Patient Advocate Foundation
Bio

 

 

PANELISTS

Christine Simmon, Senior Vice President, Policy & Strategic Alliances, Executive Director, Biosimilars Council, Association for Accessible Medicines
Bio

 

 

Sarah Yim, MD, Director, Office of Therapeutic Biologics and Biosimilars, Office of New Drugs, Center for Drug Evaluation & Research, U.S. Food and Drug Administration
Bio 

 

 

Chad Pettit, Executive Director, Global Value Access and Policy, Amgen
Bio

 

 

Madelaine Feldman, MD, Practicing Rheumatologist, President, Coalition of State Rheumatology Organizations
Bio

 

 

Resources

Articles

White Paper

Websites

  • FDA Biosimilars for access to educational materials and information about biosimilar and interchangeable products.
  • Drugs@FDA for information on all FDA approved drug products, including labeling and review information.
  • FDA Advisory Committees for drug advisory committee meetings and materials related to biosimilars
  • FDA Purple Book a database of Licensed Biological Products for information on biological products, including if products are biosimilar to a reference product.
  • Amgen Biosimilars

The Value & Innovation Forum is a collaboration of the National Forum for Heart Disease & Stroke Prevention and Patient Advocate Foundation, both 501(c)(3) nonprofit organizations. Briefing topics are selected by the Value & Innovation Forum Steering Committee which includes representatives of the Alliance of Community Health Plans, Association of Black Cardiologists, Caregiver Action Network, and National Osteoporosis Foundation, in addition to the National Forum and Patient Advocate Foundation. Briefings are made possible by funding from Amgen in accordance with the National Forum’s Policy on Corporate and Foundation Support and Relationships. This policy ensures transparency and integrity in the National Forum’s dealings with sponsors.